» Articles » PMID: 39147768

Exploring the Molecular Mechanisms and Shared Potential Drugs Between Rheumatoid Arthritis and Arthrofibrosis Based on Large Language Model and Synovial Microenvironment Analysis

Overview
Journal Sci Rep
Specialty Science
Date 2024 Aug 15
PMID 39147768
Authors
Affiliations
Soon will be listed here.
Abstract

Rheumatoid arthritis (RA) and arthrofibrosis (AF) are both chronic synovial hyperplasia diseases that result in joint stiffness and contractures. They shared similar symptoms and many common features in pathogenesis. Our study aims to perform a comprehensive analysis between RA and AF and identify novel drugs for clinical use. Based on the text mining approaches, we performed a correlation analysis of 12 common joint diseases including arthrofibrosis, gouty arthritis, infectious arthritis, juvenile idiopathic arthritis, osteoarthritis, post infectious arthropathies, post traumatic osteoarthritis, psoriatic arthritis, reactive arthritis, rheumatoid arthritis, septic arthritis, and transient arthritis. 5 bulk sequencing datasets and 4 single-cell sequencing datasets of RA and AF were integrated and analyzed. A novel drug repositioning method was found for drug screening, and text mining approaches were used to verify the identified drugs. RA and AF performed the highest gene similarity (0.77) and functional ontology similarity (0.84) among all 12 joint diseases. We figured out that they share the same key pathogenic cell including CD34 + sublining fibroblasts (CD34-SLF) and DKK3 + sublining fibroblasts (DKK3-SLF). Potential therapeutic target database (PTTD) was established with the differential expressed genes (DEGs) of these key pathogenic cells. Based on the PTTD, 15 potential drugs for AF and 16 potential drugs for RA were identified. This work provides a new perspective on AF and RA study which enhances our understanding of their pathogenesis. It also shed light on their underlying mechanism and open new avenues for drug repositioning studies.

Citing Articles

Deciphering hub genes and immune landscapes related to neutrophil extracellular traps in rheumatoid arthritis: insights from integrated bioinformatics analyses and experiments.

Li Y, Liu J, Sun Y, Hu Y, Zhou Q, Cong C Front Immunol. 2025; 15:1521634.

PMID: 39845946 PMC: 11750673. DOI: 10.3389/fimmu.2024.1521634.

References
1.
Ha M, Song Y, Jeong S, Lee H, Jung J, Kim B . Emodin inhibits proinflammatory responses and inactivates histone deacetylase 1 in hypoxic rheumatoid synoviocytes. Biol Pharm Bull. 2011; 34(9):1432-7. DOI: 10.1248/bpb.34.1432. View

2.
Li Y, Bao J, Bian Y, Erben U, Wang P, Song K . S100A4 Macrophages Are Necessary for Pulmonary Fibrosis by Activating Lung Fibroblasts. Front Immunol. 2018; 9:1776. PMC: 6088238. DOI: 10.3389/fimmu.2018.01776. View

3.
Hwang J, Noh E, Moon S, Kim J, Kwon K, Park B . Emodin suppresses inflammatory responses and joint destruction in collagen-induced arthritic mice. Rheumatology (Oxford). 2013; 52(9):1583-91. DOI: 10.1093/rheumatology/ket178. View

4.
Cheng L, Chen J, Rong X . Mechanism of Emodin in the Treatment of Rheumatoid Arthritis. Evid Based Complement Alternat Med. 2022; 2022:9482570. PMC: 9550445. DOI: 10.1155/2022/9482570. View

5.
Usher K, Zhu S, Mavropalias G, Carrino J, Zhao J, Xu J . Pathological mechanisms and therapeutic outlooks for arthrofibrosis. Bone Res. 2019; 7:9. PMC: 6433953. DOI: 10.1038/s41413-019-0047-x. View